The Legacy
How One Hormone Rewrote the Story of Growth
From Nobel Prize winners to peptide compounders, GHRH's impact continues to reshape medicine
Key Moment
From Nobel Prize discovery to compounded peptide, GHRH's journey shows how science survives when companies disappear but ideas persist.
The discovery of GHRH and the development of sermorelin did something remarkable: they changed how scientists thought about disease. For decades, hormone replacement meant one thing: give patients the hormone they are missing. Insulin for diabetics. Thyroid hormone for hypothyroidism. Growth hormone for short kids. But GHRH whispered a different idea: what if you could ask the body to heal itself? What if the broken system was not actually broken, but just sleeping?
This idea rippled outward. It changed how clinicians approached growth hormone deficiency in adults. It led to research on other hormone-releasing hormones. It inspired the search for secretagogues—drugs that stimulate hormone release instead of replacing the hormone itself. Today, the GH secretagogue class includes drugs like ghrelin mimetics, which activate ghrelin sensors to boost natural growth hormone. These are not GHRH, but they share the same philosophy: awaken the system, do not replace it. The ghrelin research itself came directly from understanding the GHRH system.
Tesamorelin represents GHRH's living legacy. It is a stabilized version of the full 44-amino acid GHRH, modified with a trans-3-hexenoic acid group attached to help it survive longer in the bloodstream. The FDA approved tesamorelin as Egrifta in 2010 for HIV-associated lipodystrophy—a condition where HIV medications cause abnormal belly fat despite overall weight loss. Tesamorelin stimulates GH release, which helps metabolize the excess fat. It works. More importantly, it proves that the basic GHRH concept still has clinical power: use the body's own signals to solve the problem.
Researchers have also studied tesamorelin for other conditions. The SMART trial tested it in aging adults for cognitive function and memory. While the primary results were modest, the idea persists: can GHRH or its analogs help aging brains? Can they improve quality of life? Some data suggest yes. Studies continue. Meanwhile, the peptide itself—the 44-amino acid form that Vale and Rivier sequenced in 1982—continues to inspire new analogs and modifications.
Sermorelin itself never truly disappeared. Compounding pharmacies kept making it. Anti-aging clinics kept prescribing it. The quality improved as regulations tightened. Today, sermorelin is available through compounding pharmacies for off-label uses: anti-aging, recovery from illness, metabolic support. It is not FDA-approved anymore, so patients and doctors must accept more risk. The FDA does not verify quality the way it does for standard drugs. But the demand persists because the idea is sound: a peptide that wakes up the natural growth system is better than external injections for many people.
Michael Thorner, the clinician who first gave GHRH to humans, continues research into growth hormone secretagogues. He and his collaborators are studying LUM-201, an oral GH secretagogue in development. The goal is the same as it was in 1982: find smarter ways to stimulate the body's own growth hormone system. The research that began with Guillemin's 5 million sheep brains continues in modern labs with modern tools.
The Guillemin-Schally story also endures. Their rivalry pushed science forward. Their shared Nobel Prize showed that competition and collaboration are not opposites—they are dance partners. Guillemin got the last word by discovering GHRH, but Schally's work on other hormones was equally important. Both lives mattered. Both legacies continue. Today, scientists read about their feud in textbooks and understand: great science often comes from great rivalry, great dedication, and people who refuse to accept that something is impossible.
GHRH's story teaches a final lesson: a perfect drug can disappear for imperfect reasons. Sermorelin was safe. It was effective. Patients trusted it. Doctors used it. But manufacturing became hard, and the company moved on. This happens in medicine more often than we admit. The answer is not to give up on good ideas. It is to build systems—compounding pharmacies, research, regulatory frameworks—that keep good ideas alive even when commercial viability fades. GHRH survived because the science was sound and the need was real.